Showing 2531-2540 of 5798 results for "".
- Dominion Aesthetic Technologies, Inc.’s eon FR Scores FDA Nodhttps://practicaldermatology.com/news/dominion-aesthetic-technologies-incs-eon-fr-scores-fda-nod/2460077/The FDA has cleared Dominion Aesthetic Technologies, Inc
- FDA Clears Allergan's CoolTone Devicehttps://practicaldermatology.com/news/fda-clears-allergans-cooltone-device/2460075/The FDA has cleared Allergan plc's CoolTone device for improvement of abdominal tone, strengthening of the abdominal muscles, and development for firmer abdomen. CoolTone is also indicated for strengthening, toning and firming of buttocks and thighs. “By partnering with A
- Aclaris Therapeutics: Positive 6-Month Results from Phase 2 Open-Label Trial of Topical ATI-502 in Androgenetic Alopeciahttps://practicaldermatology.com/news/aclaris-therapeutics-positive-6-month-results-from-phase-2-open-label-trial-of-topical-ati-502-in-androgenetic-alopecia/2460067/Results from a Phase 2 open-label clinical trial of ATI-502 (AGA-201), an investigational topical Janus Kinase (JAK) 1/3 inhibitor are promising for patients with androgenetic alopecia (AGA). Aclaris Therapeutics announced the findings and says 12-month data should be available by year’s en
- Study: Indoor Tanning Addiction May Be Abetted by Genetic and Psychiatric Factorshttps://practicaldermatology.com/news/study-indoor-tanning-addiction-may-be-abetted-by-genetic-and-psychiatric-factors/2460059/A combination of elevated symptoms of depression along with modifications in a gene responsible for dopamine activity appear to influence an addiction to indoor tanning in young, white non-Hispanic women, a new study suggests. The findings appear in the Annals of Behaviora
- Pivotal Phase 3 Trials of Trifarotene in Patients with Moderate Facial and Truncal Acne Meet All Efficacy Endpointshttps://practicaldermatology.com/news/pivotal-phase-3-trials-of-trifarotene-in-patients-with-moderate-facial-and-truncal-acne-meet-all-efficacy-endpoints-2/2460056/Results from the pivotal Phase 3 PERFECT 1 and PERFECT 2 clinical trials of once-daily trifarotene 50 µg/g cream in patients with moderate acne on the face and trunk, published in the June issue of Journal of the American Academy of Dermatology, met all primary and secondary efficacy endpoi
- BTL Taps Drew Barrymore as First Emsculpt Celebrity Ambassadorhttps://practicaldermatology.com/news/btl-taps-drew-barrymore-as-first-emscuplt-celebrity-ambassador/2460052/Drew Barrymore is Emsculpt's first celebrity ambassador. Through her partnership with Emsculpt, the actress and lifestyle mogul will share her treatment experience and results with media and on her social media channels. Ba
- Study:Colorescience’s EnviroScreen Technology Fights Sun Damage, Environmental Factorshttps://practicaldermatology.com/news/studycoloresciences-enviroscreen-technology-fights-sun-damage-environmental-factors/2460051/Colorescience’s Patented EnviroScreen Technology suppresses free radical formation and demonstrates superior performance when tested against comparable products, according to a study in The Journal of Co
- Report: Dermavant Files for $100M IPOhttps://practicaldermatology.com/news/report-dermavant-files-for-100m-ipo/2460043/Dermavant Sciences last week filed with the SEC to raise up to $100 million in an initial public offering, Renaissance Capital reports.
- Positive 90-Day Results from CONFORM Study: Recros Medicahttps://practicaldermatology.com/news/positive-90-day-results-from-conform-study-recros-medica/2460042/Ninety-day results from the CONFORM study assessing the efficacy, safety, and patient satisfaction of the Rotational Fractional Resection (RFR) procedure for submental contouring are promising. RFR is a novel, proprietary alternative to traditional approaches to treat skin laxity developed by
- FDA Approves Sorilux for Adolescent Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-sorilux-for-adolescent-plaque-psoriasis/2460039/The FDA has approved Mayne Pharma Group Limited's Sorilux (calcipotriene) Foam, 0.005% in adolescents 12 years and older. The FDA approved Sorilux in 2010 based on evidence from two eight-week placebo controlled clinical trials in patients with mild to moderate plaque psoriasis of t